On April 26, 2023 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually (Press release, Sellas Life Sciences, APR 26, 2023, View Source [SID1234630545]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Title: "A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator’s choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy."
Presenter: Omer Jamy, M.D. Principal Investigator of REGAL Study at the University of Alabama at Birmingham
Presentation Type: Poster
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Clinical Trial Registration Number: NCT04229979
Abstract Number: TPS7074
Session Date and Time: Monday, June 5, 2023, 9:00 AM – 12:00 PM EDT
Location: Hall A, On Demand
The full abstract will be published by ASCO (Free ASCO Whitepaper) on May 25, 2023 at 5:00 pm EDT.